GlassScriptPhysician profile
Satoshi S Kamada
NPI 1073630521
$5,461.41
in general payments reported to CMS, 2019-2025
25 companies · $951 in 2025
The $951 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $924 · 2021: $797 · 2022: $732 · 2023: $720 · 2024: $812 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,523.35 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,284.08 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $499.62 | 2019-2025 | |
| Novo Nordisk INC | $436.76 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $333.74 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Merck Sharp & Dohme LLC | $285.35 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $272.54 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $150.23 | 2020-2022 | |
| Amarin Pharma, INC. | $127.33 | 2020-2021 | |
| Exact Sciences Corporation | $95.14 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $86.14 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $56.00 | 2024-2025 | Zoryve |
| Daiichi Sankyo INC. | $47.36 | 2021 | |
| Genentech USA, INC. | $39.92 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.58 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $27.43 | 2023 | Crysvita |
| Optinose US, INC. | $26.31 | 2025 | |
| Sun Pharmaceutical Industries INC. | $23.97 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.66 | 2021 | |
| Glaxosmithkline, LLC. | $21.65 | 2023 | Arexvy, Shingrix |
| Seqirus USA INC | $15.81 | 2019 | |
| 3b Medical, INC. | $14.93 | 2025 | Luna |
| Arbor Pharmaceuticals, INC. | $13.23 | 2019 | |
| Therapeuticsmd, INC. | $12.64 | 2019 | |
| Zyla Life Sciences, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satoshi Kamada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.